U.S. markets closed

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4800-0.0400 (-2.63%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close1.5200
Bid1.4900 x 21500
Ask1.5000 x 21500
Day's Range1.4800 - 1.5300
52 Week Range1.0500 - 2.4000
Avg. Volume3,834,800
Market Cap471.426M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-0.2790
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Business Wire

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

  • Why Geron Corporation Stock Is Falling Today
    Motley Fool

    Why Geron Corporation Stock Is Falling Today

    Shares of clinical-stage biopharmaceutical company Geron Corporation (NASDAQ: GERN) are dropping sharply on Friday following the company's release of its fourth-quarter and full-year 2020 financial results, as well as some important clinical updates. As of 11:43 a.m. EST, Geron's stock was down by 8.7% after falling by as much as 10.1% earlier in the day. For its 2020 fourth quarter, ending on Dec. 31, Geron reported revenue (from license fees and royalties) of $50,000, compared to the revenue of $171,000 it had recorded during the prior-year quarter.

  • Yahoo Finance Video

    Gene editing will boost intelligence within ‘a few decades’

    'The Code Breaker' author and former CNN CEO Walter Isaacson joined Influencers with Andy Serwer to talk about his latest book and CRISPR technology as well as the future of bioengineering.